Krishnamegh Kunte - Molecular and population genetics of butterfly wing patterning
PROGRAM: School and Discussion Meeting on Population Genetics and Evolution PROGRAM LINK: http://www.icts.res.in/program/PGE2014 DATES: Saturday 15 Feb, 2014 - Monday 24 Feb, 2014 VENUE:...

By: ICTS Talks

Read the original post:
Krishnamegh Kunte - Molecular and population genetics of butterfly wing patterning - Video

Recommendation and review posted by Bethany Smith

Bashisth Narayan Singh - Population genetics of Drosophila ananassae
PROGRAM: School and Discussion Meeting on Population Genetics and Evolution PROGRAM LINK: http://www.icts.res.in/program/PGE2014 DATES: Saturday 15 Feb, 2014 - Monday 24 Feb, 2014 VENUE:...

By: ICTS Talks

Go here to read the rest:
Bashisth Narayan Singh - Population genetics of Drosophila ananassae - Video

Recommendation and review posted by Bethany Smith

DNA Genetics Tangie
DNA Genetics Tangie. 63 days flower.

By: oneshotgrow

Read the rest here:
DNA Genetics Tangie - Video

Recommendation and review posted by Bethany Smith

(Nasdaq:MYGN) today announced that it has submitted thefirst module of a premarket approval (PMA) application to the Food and DrugAdministration (FDA) for the use of BRACAnalysis(r) testing as a companiondiagnostic with olaparib. Olaparib is an investigational, orally activepoly-ADP ribose polymerase (PARP) inhibitor being developed by AstraZeneca. 'We believe an FDA-approved BRACAnalysis test will provide additional assurancethat patients are receiving the most accurate test results and improve patientcare by identifying candidates for treatment with olaparib,' said Mark Capone,president of Myriad Genetics Laboratories. 'Our PMA application forBRACAnalysis will provide the FDA with scientific data to evaluate the safetyand effectiveness of BRACAnalysis as a companion diagnostic.' Consistent with the FDA's modular premarket approval process, Myriad submittedthe first of four PMA modules and is working to submit the remaining modulesaccording to a pre-specified plan. The modular approach allows FDA to revieweach module as it is received and provides Myriad with timely feedback from FDAin order to help resolve issues early in the review process. 'Our PMA submission is a milestone for Myriad and BRACAnalysis is one of thefirst laboratory developed tests submitted for FDA premarket approval,' saidCapone. 'Our ability to navigate the regulatory process is benefitted by ourextensive experience in testing 1.2 million patients and our commitment to highquality.' The collaboration between Myriad and AstraZeneca on olaparib began in 2007.Since then, the two companies have shared scientific insight and worked closelytogether to move cancer research forward. In 2012, Myriad made strides indeveloping BRACAnalysis as a companion diagnostic by retrospectively genotypingpatients in a previously completed Phase 2 study of olaparib. This is apowerful example of how a companion diagnostic can advance the goals ofpersonalized medicine by stratifying patients in a clinical trial. About Myriad GeneticsMyriad Genetics is a leading molecular diagnostic company dedicated to making adifference in patients' lives through the discovery and commercialization oftransformative tests to assess a person's risk of developing disease, guidetreatment decisions and assess risk of disease progression and recurrence.Myriad's molecular diagnostic tests are based on an understanding of the rolegenes play in human disease and were developed with a commitment to improvingan individual's decision-making process for monitoring and treating disease.Myriad is focused on strategic directives to introduce new products, includingcompanion diagnostics, as well as expanding internationally. For moreinformation on how Myriad is making a difference, please visit the Company'swebsite: http://www.myriad.com. Myriad, the Myriad logo and Prolaris, Myriad myPath, Myriad myPlan, MyriadmyRisk, are trademarks or registered trademarks of Myriad Genetics, Inc. in theUnited States and foreign countries. MYGN-F, MYGN-G. Safe Harbor StatementThis press release contains 'forward-looking statements' within the meaning ofthe Private Securities Litigation Reform Act of 1995, including statementsrelating to an FDA-approved BRACAnalysis test providing additional assurancethat patients are receiving the most accurate test results and improvingpatient care by identifying candidates for treatment with olaparib; theCompany's PMA application for BRACAnalysis providing the FDA with scientificdata to evaluate the safety and effectiveness of BRACAnalysis as a companiondiagnostic; and the Company's strategic directives under the caption 'AboutMyriad Genetics.' These 'forward-looking statements' are management's presentexpectations of future events and are subject to a number of risks anduncertainties that could cause actual results to differ materially andadversely from those described in the forward-looking statements. These risksinclude, but are not limited to: the risk that sales and profit margins of ourexisting molecular diagnostic tests and companion diagnostic services maydecline or will not continue to increase at historical rates; risks related tochanges in the governmental or private insurers reimbursement levels for ourtests; the risk that we may be unable to develop or achieve commercial successfor additional molecular diagnostic tests and companion diagnostic services ina timely manner, or at all; the risk that we may not successfully develop newmarkets for our molecular diagnostic tests and companion diagnostic services,including our ability to successfully generate revenue outside the UnitedStates; the risk that licenses to the technology underlying our moleculardiagnostic tests and companion diagnostic services tests and any future testsare terminated or cannot be maintained on satisfactory terms; risks related todelays or other problems with opeRating our laboratory testing facilities;risks related to public concern over our genetic testing in general or ourtests in particular; risks related to regulatory requirements or enforcement inthe United States and foreign countries and changes in the structure of thehealthcare system or healthcare payment systems; risks related to our abilityto obtain new corporate collaborations or licenses and acquire new technologiesor businesses on satisfactory terms, if at all; risks related to our ability tosuccessfully integrate and derive benefits from any technologies or businessesthat we license or acquire; risks related to increased competition and thedevelopment of new competing tests and services; the risk that we or ourlicensors may be unable to protect or that third parties will infringe theproprietary technologies underlying our tests; the risk of patent-infringementclaims or challenges to the validity of our patents; risks related to changesin intellectual property laws covering our molecular diagnostic tests andcompanion diagnostic services and patents or enforcement in the United Statesand foreign countries, such as the Supreme Court decision in the lawsuitbrought against us by the Association for Molecular Pathology et al; risks ofnew, changing and competitive technologies and regulations in the United Statesand internationally; and other factors discussed under the heading 'RiskFactors' contained in Item 1A of our most recent Annual Report on Form 10-Kfiled with the Securities and Exchange Commission, as well as any updates tothose risk factors filed from time to time in our Quarterly Reports on Form10-Q or Current Reports on Form 8-K. All information in this press release isas of the date of the release, and Myriad undertakes no duty to update thisinformation unless required by law. CONTACT: Media Contact: Ron Rogers (801) 584-3065 rrogers@myriad.com Investor Contact: Scott Gleason (801) 584-1143 sgleason@myriad.comNews Source: NASDAQ OMXEnd of Corporate News---------------------------------07.04.2014 Dissemination of a Corporate News, transmitted by DGAP - acompany of EQS Group AG.The issuer is solely responsible for the content of this announcement.DGAP's Distribution Services include Regulatory Announcements,Financial/Corporate News and Press Releases.Media archive at http://www.dgap-medientreff.de and http://www.dgap.de---------------------------------Language: English Company: Myriad Genetics, Inc. United States ISIN: US62855J1043 End of News DGAP News-Service --------------------------------- 261855 07.04.2014

Myriad Genetics

Aktuelle Diskussionen zum Thema:

Myriad - gehts wieder aufwrts? (13.05.13) mal ber Myriad nachgedacht ? (03.07.07) Boardumfrage (an Alle) (04.01.05)

Aktuelle Nachrichten zum Unternehmen:

Myriad Genetics steigert Gewinn, . (11.08.10) Myriad Genetics verbucht deutliche. (04.11.08) Myriad Genetics prft Abspaltung . (11.09.08) Myriad Genetics verbucht krftiges. (19.08.08)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Myriad Genetics

More:
Myriad Genetics Submits Premarket Approval to FDA for BRACAnalysis(R)

Recommendation and review posted by Bethany Smith

Panel: Advanced Therapy Treatments for Cardiovascular Disease

By: Alliance for Regenerative Medicine

Read the rest here:
Panel: Advanced Therapy Treatments for Cardiovascular Disease - Video

Recommendation and review posted by sam

Panel: Commercialization Strategies Pathways to Market

By: Alliance for Regenerative Medicine

View post:
Panel: Commercialization Strategies & Pathways to Market - Video

Recommendation and review posted by sam

ISTO Technologies

By: Alliance for Regenerative Medicine

Read more here:
ISTO Technologies - Video

Recommendation and review posted by sam

Lunch Keynote Presentation
Introduction: Morrie Ruffin, Managing Director, Alliance for Regenerative Medicine Speaker: Silviu Itescu, M.B.B.S., CEO Managing Director, Mesoblast.

By: Alliance for Regenerative Medicine

Read the rest here:
Lunch Keynote Presentation - Video

Recommendation and review posted by sam

Build It So They Can Come
Leading international physicians have formed the Global Alliance for Regenerative Medicine ("GARM") in Roatan, Honduras. GARM has built a state-of-the-scienc...

By: Global Alliance for Regenerative Medicine, Roatan, Honduras

Follow this link:
Build It So They Can Come - Video

Recommendation and review posted by sam

Genetic Engineering Biology Project
I am a cute little girl in jeans.

By: Scott Diliberto

View post:
Genetic Engineering Biology Project - Video

Recommendation and review posted by Bethany Smith

The Genetic Engineering Of The Annunaki Gods - Chris Hardy
Cognitive and systems scientist, Chris Hardy joins Dr. Rita Louise on Just Energy Radio where she discusses the history of the Anunnaki on the Earth and thei...

By: Just Energy Radio

View post:
The Genetic Engineering Of The Annunaki Gods - Chris Hardy - Video

Recommendation and review posted by Bethany Smith

April 5, 2014

April Flowers for redOrbit.com Your Universe Online

Endometriosis is a chronic inflammatory disease that affects more than 176 million women and girls worldwide, according to the Endometriosis Foundation of America. Despite being one of the most common gynecological disorders, there is no definitive consensus on the cause of endometriosis. To add insult to injury, some women who have endometriosis are also predisposed to ovarian cancer.

A new study from the University of Pittsburgh Cancer Institute (UPCI) and Magee-Womens Research Institute (MWRI) reveals that genetic screening could someday help clinicians to know which women are most at risk.

The research team will present their results on the first comprehensive immune gene profile exploring endometriosis and cancer on Monday at the American Association for Cancer Research (AACR) Annual Meeting 2014.

A small subset of women with endometriosis go on to develop ovarian cancer, but doctors have no clinical way to predict which women, said Anda Vlad, MD, PhD, assistant professor of obstetrics, gynecology and reproductive sciences at MWRI. If further studies show that the genetic pathway we uncovered is indicative of future cancer development, then doctors will know to more closely monitor certain women and perhaps take active preventative measures, such as immune therapy.

Endometriosis is a painful condition that is often misdiagnosed for years before some form of correct treatment is attempted. As redOrbit reported in February, it is called a disease of theories, because so little is known about how it works, or who it will strike.

We know there is a genetic component, we know there is an environmental component, and we know there is an inflammatory component. But its very difficult to say for individual patients what particular sequence of events led to particular symptoms, Michael Beste, a postdoc in MITs Department of Biological Engineering, said.

It is the genetic component, and its association to cancer, that Vlad and her team are focused on finding.

Vlad and her team screened tissue samples from women with benign endometriosis, women with precancerous lesions and women with endometriosis-associated ovarian cancer. This allowed the researchers to identify the complement pathway, which refers to a series of protein interactions that trigger an amplified immune response, as the most prominent immune pathway that is activated in both endometriosis and endometriosis-associated ovarian cancer.

See the article here:
Genetic Screening For Endometriosis-Associated Ovarian Cancer

Recommendation and review posted by Bethany Smith

Some patients with a suspected genetic disorder will go on what medical professionals call a diagnostic odyssey to find the cause of their symptoms.

A sample is run through the HiSeq 2000, a high-throughput sequencing system in the DNA lab at the University of Iowa Eckstein Medical Research Building in Iowa City. The green dots on the screen show a cluster of the fragment being sequenced. The lab also uses a HiSeq 2500, which can complete sequencing in 27 hours to the HiSeq 2000's 12 days. The Iowa Institute of Human Genetics at the University of Iowa is now offering whole exome sequencing, which is among several initiatives the institute is pursuing to further personalize medicine for patients. (Liz Martin/The Gazette-KCRG)

But those explorations, on occasion, can come up empty, frustrating patients and prompting health care providers to seek outside expertise.

Last month, the Iowa Institute of Human Genetics at the University of Iowa began offering such expertise through whole exome sequencing.

The genetic test, which analyzes a portion of about 20,000 genes in the human genome in hopes of helping practitioners diagnose and treat a patient, is among several initiatives the institute is pursuing to further personalize medicine for patients in Iowa and across the country.

The research we do here is to develop new tests to bring precision medicine to the state, said Colleen Campbell, assistant director of the Iowa Institute of Human Genetics and associate with the UI Department of Otolaryngology.

Researchers with the institute also are conducting tests around secondary findings from exome sequencing the discovery of variants in genes unrelated to a patients primary condition and how a persons genes interact with prescribed medication, including pain medication.

The technology is new, but officials with the Iowa institute said genetic sequencing one day could become so widely used that every infant will have it done as part of the standard newborn screen. Then, as a child grows, practitioners will be able to use the information to determine what type of pain medication to prescribe and at what level, for example.

Our focus is to bring innovation to the state, Campbell said. We want patients to be more informed when they go to the doctor and are offered these new tests. And we want to be able to offer this as a tool to doctors.

The Iowa Institute of Human Genetics is among only a dozen or so institutions nationally that offer whole exome sequencing to physicians wanting to order the test on behalf of a patient.

Continued here:
University of Iowa hopes to use sequencing to better diagnose and treat patients

Recommendation and review posted by Bethany Smith

Tangie Project From Seed To Seed - Tangie - Transfering the Seeds
In this video we are going to soak our Tangie seeds. Place them in the container with clean water and leave for four hours. We have 13 seeds here and as you ...

By: Genesis 1:11 Genetics

Excerpt from:
Tangie Project From Seed To Seed - Tangie - Transfering the Seeds - Video

Recommendation and review posted by Bethany Smith

Tangie. Project From Seed To Seed - Tangie - Starting Seeds
Here we are again with our Tangie seeds! In the previous video we soaked them in water for 4 hours and now we ready to transfer them in wet paper towel where...

By: Genesis 1:11 Genetics

Continue reading here:
Tangie. Project From Seed To Seed - Tangie - Starting Seeds - Video

Recommendation and review posted by Bethany Smith

The Social Grow/Skunk house Genetics,,Amazing Grace uPdate #6
WK #5 ,New Genetics, got me wanting to leave the bagseeds alone...haha.I DO NOT OWN MUSIC RIGHTS...18 OVER PLEASE...

By: OrganicGrowslife

See the original post:
The Social Grow/Skunk house Genetics,,Amazing Grace uPdate #6 - Video

Recommendation and review posted by Bethany Smith

Tangie. Project From Seed To Seed - Tangie - First Sprout
Next video for our Tangie project! It has been 30 hours since we placed them in the wet paper towel. You can start checking at 24 hours if you want. We can s...

By: Genesis 1:11 Genetics

View original post here:
Tangie. Project From Seed To Seed - Tangie - First Sprout - Video

Recommendation and review posted by Bethany Smith

Population and Genetics Genesis Week, Episode 20, season 2 with Wazooloo Ian Juby
see the link section 6.5 for the math which brings us a .49% growth rate. Population growth is modeled by the equation P = P0(1 + r)t, where P is the current...

By: Phillip Wales

More here:
Population and Genetics Genesis Week, Episode 20, season 2 with Wazooloo Ian Juby - Video

Recommendation and review posted by Bethany Smith

Diabetes- Genetics Project
My First Project.

By: Samantha Steckman

Visit link:
Diabetes- Genetics Project - Video

Recommendation and review posted by Bethany Smith

Genetics Part 11: Transcription 1 (In Prokaryotes)
Introductory video on transcription: RNA polymerase subunits and their function, Monocistronic and polycistronic transcription unit, sense and antisense strand.

By: Debalina Mukhopadhyay

See the article here:
Genetics Part 11: Transcription 1 (In Prokaryotes) - Video

Recommendation and review posted by Bethany Smith

Genetics Part 13: Transcription 3 (Transcription termination)
This video describes the promoter sequence in prokaryotic transcription unit, different kind of sigma factor, transcription termination by intrinsic terminat...

By: Debalina Mukhopadhyay

Read more:
Genetics Part 13: Transcription 3 (Transcription termination) - Video

Recommendation and review posted by Bethany Smith

Museum Genetics

By: Maxim Azarov

Read this article:
Museum Genetics - Video

Recommendation and review posted by Bethany Smith

Laser Genetics 3.5-10x50mm Rifle Scope
http://video.sportsmansguide.com/?v=1695643256 Laser Genetics 3.5-10x50mm Rifle Scope: watch this video featuring products available on The Sportsmans Guide.

By: sportsmansguide

Continue reading here:
Laser Genetics 3.5-10x50mm Rifle Scope - Video

Recommendation and review posted by Bethany Smith

Are We Close To Repairing Spinal Cord Injuries?
Certain injuries we are able to fix, and some we simply don #39;t have the technology to fix. One of the more common unfixable of these are spinal cord injuries,...

By: DNews

View original post here:
Are We Close To Repairing Spinal Cord Injuries? - Video

Recommendation and review posted by Bethany Smith

Mesoblast on FOX News - Treating back pain with adult stem cells
FOX Network News announced the promising news of the results of a clinical trial that the reporter says is "pretty cool stuff.... and the results have been s...

By: AHPRvideo

More:
Mesoblast on FOX News - Treating back pain with adult stem cells - Video

Recommendation and review posted by simmons